{
  "ticker": "BXN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960166",
  "id": "02960166",
  "pages": 14,
  "price_sensitive": true,
  "date": "20250619",
  "time": "1657",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kxfgr0hd69dm.pdf",
  "summary": "### **Material Information Summary (Bioxyne Investor Presentation \u2013 June 2025)**  \n\n#### **Operational & Financial Highlights**  \n- **Australian Operations:**  \n  - Manufacturing scale: ~15M pastilles (~110K finished products/month).  \n  - **Current sales run rate:** $3M/month (~$36M annualized).  \n  - Supplies ~15% of Australia\u2019s medical cannabis flower.  \n\n- **European Expansion:**  \n  - **$5.6M** minimum contracted revenue (FY2026, one client).  \n  - EU GMP certification secured; targeting **20T/year** flower packing capacity.  \n\n- **UK Market:**  \n  - First shipment valued at **~A$2.5M** (sale to clinics).  \n  - Signed distribution deals covering **60K patients**.  \n\n- **Psychedelics (MDMA/Psilocybin):**  \n  - Commercial-ready MDMA capsules (40mg/100mg); **first revenues July 2025**.  \n  - Psilocybin imports (10kg fungi + 10g synthetic API) secured for **5K+ doses**.  \n\n- **FY2025 Revenue Guidance:**  \n  - **Upgraded to $28M** (from $25M).  \n  - **50% gross margin** (pre-commissions); full-year profitable & cashflow positive.  \n\n#### **Key Takeaways for Trading**  \n1. **Revenue growth accelerated** (50% YoY implied from FY24A to FY25F).  \n2. **European/UK contracts de-risk near-term revenue** ($5.6M FY2026 minimum).  \n3. **Psychedelics commercialization imminent** (July 2025 launch).  \n\n*Omitted: Forward-looking disclaimers, operational minutiae, non-quantitative claims.*",
  "usage": {
    "prompt_tokens": 2886,
    "completion_tokens": 385,
    "total_tokens": 3271,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T07:36:27.564747"
}